Leukocyte Differential Compared on Flow Cytometry Hematology Analyzer
|
By LabMedica International staff writers Posted on 10 Sep 2012 |

Image: The DxH 800 Cellular Analysis System (Photo courtesy of Beckman Coulter).
A recently introduced automated hematology analyzer that provides a 16-part white blood cell count (WBC) differential has been compared with other automated machines and the manual method.
The newer flow cytometry-hematology analyzer is not only able to differentiate the five main white cell populations but also capable of distinguishing 11 other cells including immature blast cells and various T-lymphocytes.
Scientists at Dong-A University (Busan, South Korea) selected 101 blood samples in routine complete blood counts (CBC) for analysis regardless of previous diagnosis. The samples came from 54 men and 47 women, whose age range was 1-84 years, with a mean age of 43 years. The Hematoflow, the newest automatic hematology analyzer, includes a DxH 800 Coulter Cellular Analysis System and FC 500 Flow Cytometer (Beckman Coulter; Miami, FL, USA). The DxH800 uses multiple angles of light scatter, and the FC500 provides a 16-part WBC differential, giving precise information on WBC subsets.
The FC500 contains a premixed Cytodiff reagent and analysis software. The Cytodiff panel included six directly conjugated monoclonal antibodies in a five-color single reagent. The differential WBC count performance of the FC500, was compared with the Beckman Coulter DxH800, the Sysmex XE-2100 (TOA Medical Electronics Co.; Kobe, Japan), and the reference manual method. The methodological comparison of the WBC differential parameters of neutrophils, lymphocytes, monocytes and eosinophils showed good correlations among four different analyses. More than 1% of blast cells were counted in 30 of 101 samples.
For B-cell acute lymphatic leukaemia (ALL), blast B count of Hematoflow shows good correlation with reference method results. The analyzer easily distinguished B-cell lineage leukemic blasts from T-cell leukemic blasts and myeloblasts. For T-cell ALL, Hematoflow did not identify blast T, and shows complete agreement with manual counting. For acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), blast non-B-non-T counts of Hematoflow shows 100% concordance and good correlation with reference method results.
The scientists concluded that for the technical staff, the installation of Hematoflow would have many consequences. There would be a reduction in technical staff time at the microscope while simultaneously increasing the efficiency of the workflow, the elimination of medical technologists facing a difficult diagnosis alone. This rapid and quantitative technique may be helpful in the differential diagnosis of acute leukemias prior to additional investigation. The study was published in the October 2012 edition of the International Journal of Laboratory Hematology.
Related Links:
Dong-A University
Beckman Coulter
TOA Medical Electronics Co.
The newer flow cytometry-hematology analyzer is not only able to differentiate the five main white cell populations but also capable of distinguishing 11 other cells including immature blast cells and various T-lymphocytes.
Scientists at Dong-A University (Busan, South Korea) selected 101 blood samples in routine complete blood counts (CBC) for analysis regardless of previous diagnosis. The samples came from 54 men and 47 women, whose age range was 1-84 years, with a mean age of 43 years. The Hematoflow, the newest automatic hematology analyzer, includes a DxH 800 Coulter Cellular Analysis System and FC 500 Flow Cytometer (Beckman Coulter; Miami, FL, USA). The DxH800 uses multiple angles of light scatter, and the FC500 provides a 16-part WBC differential, giving precise information on WBC subsets.
The FC500 contains a premixed Cytodiff reagent and analysis software. The Cytodiff panel included six directly conjugated monoclonal antibodies in a five-color single reagent. The differential WBC count performance of the FC500, was compared with the Beckman Coulter DxH800, the Sysmex XE-2100 (TOA Medical Electronics Co.; Kobe, Japan), and the reference manual method. The methodological comparison of the WBC differential parameters of neutrophils, lymphocytes, monocytes and eosinophils showed good correlations among four different analyses. More than 1% of blast cells were counted in 30 of 101 samples.
For B-cell acute lymphatic leukaemia (ALL), blast B count of Hematoflow shows good correlation with reference method results. The analyzer easily distinguished B-cell lineage leukemic blasts from T-cell leukemic blasts and myeloblasts. For T-cell ALL, Hematoflow did not identify blast T, and shows complete agreement with manual counting. For acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), blast non-B-non-T counts of Hematoflow shows 100% concordance and good correlation with reference method results.
The scientists concluded that for the technical staff, the installation of Hematoflow would have many consequences. There would be a reduction in technical staff time at the microscope while simultaneously increasing the efficiency of the workflow, the elimination of medical technologists facing a difficult diagnosis alone. This rapid and quantitative technique may be helpful in the differential diagnosis of acute leukemias prior to additional investigation. The study was published in the October 2012 edition of the International Journal of Laboratory Hematology.
Related Links:
Dong-A University
Beckman Coulter
TOA Medical Electronics Co.
Latest Hematology News
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








